Rheumatology Medical News about Colchicine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial
Modern Rheumatology, 07/16/09

Davatchi F et al. - Colchicine, but not placebo, significantly improved the overall disease activity index. The difference between the results for colchicine and placebo was also statistically significant.

Exclusive Author Commentary
Fereydoun Davatchi, 07/17/09

Both in intention to treat analysis and in completed patients' analysis colchicine improved significantly mucocutaneous manifestations (oral aphthosis, genital aphthosis, and skin lesions) but not the placebo. No difference in the response rate was found between men and women, as reported before. A statistically significant difference was also found between colchicine and placebo for joint manifestations. Therefore, colchicine is an effective treatment in Behcet’s Disease for mucocutaneous and joint manifestations. However, its ability to improve, or to prevent from major organ involvement, is not yet demonstrated and warrants further studies.

<< Previous
A Study of Bone Mineral Density in Adults With Disability

Next >>
Prevalence and Progression of Osteoporosis in Patients With COPD